More M&A is key to Stryker's strategy to build higher 2014 sales through investments in innovation and globalization, and the Michigan device company now says it will snatch up a German surgical equipment maker for $172 million.
After two proxy battles with Forest Labs and a settlement that warded off a third, longtime rebel investor Carl Icahn finally got his way Tuesday when Actavis announced its $25 billion buyout of the New York City-based company.
GSI group, which makes photonics and motion control components, will buy up Jadak, a company that develops OEM components exclusively for the med tech space, for $93.5 million.
Singapore's Biosensors International has reportedly become an acquisition target. A Chinese private equity firm with a stake in the medical device company is said to be looking into snatching up the remaining shares it doesn't already own.
Actavis is extending its deal spree with another big buyout. The generics maker has agreed to buy Forest Laboratories for about $25 billion, in a bid to further build up its presence in branded drugs.
For Actavis, the deal would deliver a new set of drugs for marketing, part of its core M&A strategy as Watson first snapped up Actavis, took the Swiss company's name and then engineered a $5 billion buyout of Warner Chilcott, gaining an Irish domicile and the considerable tax advantages that go with it.
BioMarin Pharmaceuticals nabbed the FDA's blessing for Vimizim, the only drug ever approved to treat a rare enzyme disorder called Morquio A syndrome, although it will wear a boxed warning about the risk of anaphylaxis. The FDA nod could set the M&A rumor mill to work again.
Novartis is gobbling up a startup biotech in the U.S. that could help provide an entry into the frenzied race for PD-1 targeting therapies, announcing this morning that it had struck a deal to buy CoStim Pharmaceuticals, a low-profile biotech based in Cambridge, MA, and listed as part of Atlas Venture's group of companies.
The biotech has struck a deal with little Prothelia and the University of Nevada, Reno, where it will step in and conduct development research on a protein replacement therapy for merosin-deficient congenital muscular dystrophy, or MDC1A.
When hedge fund veteran Martin Shkreli debuted Retrophin, his biotech play, more than few market watchers reacted with healthy skepticism and even open mockery. But now the company's plans to cash in with a rare-disease treatment have made it a hit with investors, with shares skyrocketing more than 40%.